Filter Results
:
(29)
Show Results For
- All HBS Web (29)
- Faculty Publications (7)
Show Results For
- All HBS Web (29)
- Faculty Publications (7)
Page 1 of
29
Results
→
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused...
View Details
Keywords:
Gene Therapy;
Gene Editing;
Impact;
Health Care and Treatment;
Technological Innovation;
Health Testing and Trials;
Venture Capital;
Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- January 2018
- Case
Spark Therapeutics: Pioneering Gene Therapy
By: Robert F. Higgins and Tina Liu
Spark Therapeutics is a pioneering gene therapy startup. It was spun out of The Children’s Hospital of Philadelphia (CHOP). The company had taken with it much of the intellectual property and talent that CHOP had developed. The company is considering an initial public...
View Details
Keywords:
Health Care and Treatment;
Innovation and Invention;
Business Startups;
Opportunities;
Problems and Challenges;
Strategy
Higgins, Robert F., and Tina Liu. "Spark Therapeutics: Pioneering Gene Therapy." Harvard Business School Case 818-059, January 2018.
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
Keywords:
AI;
Genetic Engineering;
Medicine;
Health Care and Treatment;
Genetics;
Innovation Strategy;
Business and Stakeholder Relations;
Medical Specialties;
Innovation and Invention;
Entrepreneurship;
Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 27 Sep 2015
- News
Pharma gives drug development the Hollywood treatment
- October 2016 (Revised September 2017)
- Case
The CRISPR-Cas9 Quarrel
By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to...
View Details
Keywords:
CRISPR;
Broad Institute;
University Of California Berkeley;
Intellectual Property;
Patents;
Law;
Lawsuits and Litigation;
Science;
Genetics;
Entrepreneurship;
Biotechnology Industry;
United States
Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised September 2017.)
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing...
View Details
Keywords:
Venture Capital;
Business Startups;
Entrepreneurship;
Investment;
Business Strategy;
Financial Services Industry;
Biotechnology Industry;
United States;
Ohio
Gompers, Paul A., and Alicia Dadlani. "Drive Capital: A New Road for Venture." Harvard Business School Case 823-056, April 2023.
- September 2020 (Revised July 2021)
- Case
Moderna (A)
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer and Kerry Herman
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital...
View Details
Keywords:
COVID-19;
Vaccine;
Digital Organizations;
Organizational Structure;
Operations;
Management;
Health Pandemics;
Research and Development;
Goals and Objectives
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, and Kerry Herman. "Moderna (A)." Harvard Business School Case 621-032, September 2020. (Revised July 2021.)
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
predict a new world where drug treatments are customized to an individual's genetic makeup, and gene-based therapy can root out cancer and other diseases before they take hold in the body. The new science will "revolutionize the way...
View Details
Keywords:
by Sean Silverthorne
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19....
View Details
- Web
Curriculum - MBA
students discuss classical and contemporary papers fundamental to the current biotechnology revolution (such as those underpinning the use of monoclonal antibodies, stem-cell transplantation, neural stimulation and regeneration, and gene...
View Details
- Web
Faculty & Advisors - MBA
for nearly 20 years at JDRF, the leading public charity in T1D. He is a former director of Provention Bio (NASDAQ: PRVB), which obtained approval for the first disease-modifying therapy in T1D and which has agreed to be acquired by...
View Details
- 07 Feb 2024
- News
The Sound of Success
A groundbreaking gene therapy developed by Akouos, Inc., a precision genetic medicine company founded in 2016 by Emmanuel (Manny) Simons (MBA 2012), has enabled an 11-year-old boy from Morocco to hear sounds for the first time. According to a recent New York Times...
View Details
- 01 Jun 2023
- News
From Big Pharma to Startup
Hunter Goble (MBA 2022) did not enroll in Harvard Business School with dreams of becoming an entrepreneur. After earning his MBA, Goble intended to return to Eli Lilly to continue to work building brands and launching products. He envisioned himself leading a big,...
View Details
Keywords:
April White
- 09 Oct 2020
- Blog Post
4 Things To Know About the MS/MBA Biotech
gene therapy company to apply my newly acquired knowledge of the health care industry to a biotechnology company led by creative thinkers with the mission of transformative care. In my first few weeks at the...
View Details
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
prices and expand access to life-saving therapies,” she says. After college, Rabah joined the biotech company Sio Gene Therapies, where she had the opportunity to speak with parents of children with Tay-Sachs disease, an ultra-rare...
View Details
- Web
Rare Disease Day – Small Numbers, Big Challenges… and Big Opportunities - Blog: Health Supplement
atmosphere for new rare disease treatment options. The most exciting area of opportunity is in genomics and precision medicine (expected to be a $175B market by 2030). With 72% of rare diseases having genetic origins, the potential of a world with tailored View Details
- Web
Annual Report 2020 - Annual Report 2020
science startups) Tune Bio Unlocks next-generation gene therapies through regulatory element engineering. STUDENT SOCIAL ENTERPRISE TRACK WINNERS Peter M. Sacerdote Grand Prize: Mosaic Provides a complete...
View Details
- 01 Dec 2013
- News
Innovation as Antidote
inspiration typically comes from a very human place. DART Therapeutics CEO Gene Williams (MBA 1987) ("Your Own Medicine"), for instance, told us about a revelation he had during a 2002 trip to Rotterdam to observe clinical trials for the...
View Details
Keywords:
Health, Social Assistance
- 06 Dec 2021
- News
Vision: Sound Science
as sound. Getting a healthy copy of the critical gene to the appropriate cells is a solution, but precision inner-ear drug delivery has been a historical stumbling block. An early breakthrough for us was figuring out a way to pair View Details
Keywords:
Deb Blagg
- 01 Dec 2013
- News
Your Own Medicine
compounds owned by struggling biotechs. Williams usually calls Tracy once or twice a day, with about a dozen emails back and forth daily. Things are moving. Long term, the Secklers see stem cell or gene replacement View Details